Suchergebnisse - "Palmieri, Salvatore"

PubPharm (11)

1

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

enthalten in: The New England journal of medicine | 2024

von Sonneveld, P. | Dimopoulos, M. | Boccadoro, M. | +141

CommentIn: N Engl J Med. 2024 Apr 18;390(15):1440. - PMID 38631009

2

Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma : a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials

enthalten in: Haematologica | 2024

von Gentile, M. | Vigna, E. | Palmieri, S. | +44

3

Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients : italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials

enthalten in: Hematological oncology | 2022

von Martino, E. | Conticello, C. | Zamagni, E. | +30

4

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma : Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials

enthalten in: Hematological oncology | 2022

von Bruzzese, A. | Derudas, D. | Galli, M. | +57

5

Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients

enthalten in: European journal of haematology | 2022

von Morabito, F. | Zamagni, E. | Conticello, C. | +41

6

Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma : Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials

enthalten in: Haematologica | 2021

von Gentile, M. | Specchia, G. | Derudas, D. | +53

7

KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life : a retrospective survey in 123 patients

enthalten in: Annals of hematology | 2020

von Palmieri, S. | Rocco, S. | Vitagliano, O. | +17

8

KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients

enthalten in: Annals of hematology | 2020

von Palmieri, S. | Rocco, S. | Vitagliano, O. | +17

9

KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients

enthalten in: Annals of hematology | 2020

von Palmieri, S. | Rocco, S. | Vitagliano, O. | +17

10

KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients

enthalten in: Annals of hematology | 2020

von Palmieri, S. | Rocco, S. | Vitagliano, O. | +17